Genmab announces Arzerra development plans

8 March 2016

Danish biotech company Genmab (OMX: GEN) has announced new plans for its autoimmune development activities which will focus on relapsing multiple sclerosis, including Phase III studies with subcutaneous formulation of Arzerra (ofatumumab).

The update comes following the transfer of the rights to Arzerra in this disease area from GlaxoSmithKLine (LSE: GSK) to Novartis (NOVN: VX) at the end of 2015.

Phase III studies are expected to be initiated by Novartis with the subcutaneous formulation of Arzerra as therapy for patients with relapsing multiple sclerosis during the second half of 2016.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK